Login to Your Account

Financings Roundup

AAA Gets $57M for Pivotal Cancer Drug Trial, Acquisition

By Cormac Sheridan

Monday, July 25, 2011
Advanced Accelerator Applications S.A. (AAA) closed a €40 million ($57.4 million) funding round that will enable the company to move its lead drug candidate Lutathera (lutate; 177Lutetium DOTA0-Tyr3-Octreotate) into pivotal trials in cancer later this year and to complete the acquisition of an as yet undisclosed firm that is developing a drug for ovarian cancer.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription